Study guide

18.6 Sjogren's Syndrome & Inflammatory Myopathies

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

18.6 Sjogren's Syndrome & Inflammatory Myopathies

Key Takeaways Explain This Topic AI

Anti-Ro antibodies cross the placenta and cause congenital heart block, so they must be checked before pregnancy in connective tissue disease.

Dermatomyositis presents with a heliotrope rash, Gottron papules and proximal weakness, and in adults carries a substantial risk of occult malignancy.

Antisynthetase syndrome (anti-Jo-1) combines myositis, interstitial lung disease, Raynaud phenomenon, arthritis and mechanic's hands.

Last updated: September 2026

7. Sjögren's Syndrome

Sjögren's syndrome is a chronic autoimmune epithelitis characterized by progressive CD4+ T-cell and B-cell lymphocytic infiltration of exocrine glands, predominantly the lacrimal and salivary glands.

Clinical Features & Diagnostic Assessment

Sicca Complex:

Xerophthalmia (Keratoconjunctivitis Sicca): Sensation of gritty ocular foreign body, burning, photophobia, and dry eyes. Assessed clinically using Schirmer's test (a strip of filter paper placed in the lower conjunctival sac; < 5 mm wetting after 5 minutes is abnormal ) or Rose Bengal / fluorescein corneal staining revealing punctate epitheliopathy.

Xerostomia: Severe oral dryness, requiring water to swallow dry food, dysgeusia, accelerated rampant dental caries (particularly cervical and incisal caries), and recurrent oral candidiasis.

Glandular Enlargement: Bilateral, firm, non-tender or mildly tender parotid gland enlargement in 30–40% of patients.

Extraglandular Features: Arthralgias, fatigue, Raynaud's phenomenon, cutaneous purpuric vasculitis, and renal tubular acidosis ( Type 1 distal RTA causing hypokalaemic metabolic acidosis, nephrocalcinosis, and osteomalacia).

Diagnostic Autoantibodies: Anti-Ro/SSA (positive in 60–80%) and Anti-La/SSB (positive in 40–60%). Positive Rheumatoid Factor is present in 70% of primary Sjögren's patients, along with polyclonal hypergammaglobulinaemia.

Histopathological Gold Standard: Minor salivary gland lip biopsy demonstrating focal lymphocytic sialadenitis, defined by a Chisholm-Mason focus score >= 1 (at least one dense aggregate of >= 50 mononuclear cells per 4 mm² of glandular tissue).

Major Neoplastic Complication: B-Cell MALT Lymphoma

Patients with primary Sjögren's syndrome carry an extraordinary up to 44-fold increased relative risk of developing Non-Hodgkin Lymphoma , specifically marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue [MALT] lymphoma) , typically arising within the salivary glands, stomach, lungs, or thyroid.

Red Flags for Lymphomatous Transformation:

  • Persistent, firm, asymmetrical or expanding enlargement of a parotid or submandibular gland;
  • Disappearance of previously elevated Rheumatoid Factor levels;
  • Development of new hypocomplementaemia (particularly low C4) ;
  • Presence of type II mixed cryoglobulinaemia or a new serum monoclonal paraprotein spike (M-band);

Development of cutaneous palpable purpura, lymphadenopathy, or systemic B-symptoms (unexplained fever, drenching night sweats, weight loss).

8. Inflammatory Myopathies: Polymyositis, Dermatomyositis & Antisynthetase Syndrome

Idiopathic inflammatory myopathies are autoimmune disorders targeting skeletal muscle and surrounding microvasculature.

Clinical Presentation

Proximal Symmetrical Muscle Weakness: Insidious or subacute progressive weakness affecting proximal limb-girdle musculature (pelvic and shoulder girdles). Patients report difficulty rising from a low chair, climbing stairs, lifting objects into overhead cupboards, and combing their hair. Distal muscles are preserved until late. Facial and extraocular muscles are characteristically SPARED (in stark contrast to myasthenia gravis, which classically causes ptosis, diplopia, and ocular paresis).

Bulbar & Respiratory Involvement: Oropharyngeal and upper oesophageal striated muscle weakness causes dysphagia, dysarthria, and aspiration pneumonia. Diaphragmatic and intercostal weakness precipitates ventilatory failure.

Serum Enzymes: Markedly elevated Creatine Kinase (CK) , frequently 10 to 50 times the upper limit of normal (often 5,000–20,000 U/L). Elevated aldolase, AST, ALT, and LDH.

Pathognomonic Cutaneous Hallmarks of Dermatomyositis

Heliotrope Rash: Violaceous (purplish-pink) macular erythema of the upper eyelids and periorbital tissues, frequently accompanied by periorbital oedema.

Gottron's Papules: Pathognomonic erythematous or violaceous, flat-topped, lichenoid scaly papules and plaques overlying the dorsal aspect of the metacarpophalangeal (MCP) and interphalangeal (PIP, DIP) joints . CRUCIAL EXAM CONTRAST: Gottron's papules affect the skin overlying the joints, whereas the rash of SLE characteristically spares the knuckle joints and affects the skin in between the joints!

Gottron's Sign: Symmetrical macular violaceous erythema over extensor bony prominences (elbows, knees, medial malleoli).

Shawl Sign & V-Sign: Poikiloderma (mottled erythema, telangiectasia, dyspigmentation) in a photosensitive distribution across the upper back, posterior neck, and shoulders ( shawl sign ) or anterior lower neck and chest ( V-sign ).

Mechanic's Hands: Hyperkeratotic, cracked, painful fissuring and scaling along the radial and palmar aspects of the fingers and palms, resembling the hands of a manual laborer.

Diagnostic Autoantibodies & Clinical Associations

Anti-Jo-1 (Anti-Histidyl-tRNA Synthetase): The prototypical myositis-specific antibody (20–30% of patients). Defines the Antisynthetase Syndrome , characterized by the clinical pentad:

  • Inflammatory myositis;
  • Rapidly progressive interstitial lung disease (ILD) ;
  • Raynaud's phenomenon;
  • Non-erosive inflammatory arthritis; and

Mechanic's hands .

Anti-Mi-2: Directed against a helicase involved in transcription. Strongly associated with classic dermatomyositis, prominent cutaneous Gottron's/heliotrope lesions, excellent response to systemic corticosteroids, and a very low malignancy risk.

Anti-TIF1-gamma (TRIM33) & Anti-NXP-2: Strongly associated with cancer-associated dermatomyositis in adults . Up to 50–70% of adult dermatomyositis patients harboring anti-TIF1-gamma have an underlying occult malignancy (ovarian, lung, breast, colorectal, or lymphoma). Mandatory clinical action: Any adult diagnosed with dermatomyositis (especially if anti-TIF1-gamma or anti-NXP-2 positive) must undergo comprehensive occult malignancy screening (CT chest/abdomen/pelvis, mammography, pelvic ultrasound/CA-125, PSA, and colonoscopy).

Anti-SRP: Associated with severe, rapidly progressive necrotizing autoimmune myopathy, profound weakness, cardiac involvement, and poor steroid response.

Anti-HMG-CoA Reductase (Anti-HMGCR): Associated with statin-induced necrotizing autoimmune myopathy . Persistent, progressive muscle weakness and massive CK elevation that continues to deteriorate despite statin discontinuation ; requires aggressive immunosuppressive therapy.

Muscle Biopsy: Polymyositis vs. Dermatomyositis

  • Feature Polymyositis (PM) Dermatomyositis (DM)
  • Primary Target Muscle fibre (myocyte) parenchymal injury Endomysial microvasculature (endothelium)

Inflammatory Infiltrate Endomysial infiltrate directly surrounding and invading non-necrotic muscle fibres Perimysial and perivascular infiltrate surrounding blood vessels and muscle fascicles

Predominant Lymphocytes Cytotoxic CD8+ T cells and macrophages CD4+ helper T cells , B cells, and plasmacytoid dendritic cells

MHC Class I Expression Widespread diffuse upregulation on non-necrotic fibres Upregulation predominantly in perifascicular areas

Pathognomonic Histology Intracellular CD8+ invasion of healthy myofibres Perifascicular Atrophy (atrophy and necrosis of muscle fibres at the outer periphery of fascicles)

Vascular Pathology Normal endomysial capillaries Complement MAC (C5b-9) deposition on capillary walls; capillary dropout

9. Comparative Synthesis: Limited vs. Diffuse Systemic Sclerosis

Diagnostic Domain Limited Cutaneous SSc (lcSSc / CREST) Diffuse Cutaneous SSc (dcSSc)

Skin Distribution Distal to elbows and knees; face; spares trunk Proximal to elbows/knees; involves trunk and abdomen

Raynaud's Phenomenon Precedes skin involvement by years to decades Precedes skin changes by weeks to months or appears concurrently

Characteristic Serology Anti-Centromere Antibodies (ACA) (70–80%) Anti-Scl-70 (Topoisomerase I) (30–40%) / Anti-RNA Pol III (20%)

Major Pulmonary Complication Isolated Pulmonary Arterial Hypertension (PAH) Severe Interstitial Lung Disease (ILD / Fibrosis)

Pulmonary Function Profile Isolated low DLCO with normal/preserved FVC Restrictive defect (reduced FVC) with proportional low DLCO

Renal Complication Scleroderma Renal Crisis is rare (< 2%) Scleroderma Renal Crisis common (10–15%; anti-RNA Pol III)

Trigger for Renal Crisis High-dose corticosteroids Corticosteroid exposure (prednisolone > 15 mg/day)

Emergency Renal Treatment ACE inhibitors (oral captopril) Emergency ACE inhibitors (oral captopril) titrated aggressively

Long-Term Prognosis Better overall survival; late mortality from PAH Poorer overall survival; early mortality from ILD, SRC, or cardiac